

# A quick reference tool to facilitate initiation of <sup>Pr</sup> JINARC<sup>®</sup> for your patients

## The JINARC Controlled Hepatic Safety Monitoring and Distribution (HSMD) Programme

Patient name:	Patient date of birth:
Patient ID # (Clinic identifier):	Current date:

**Use this checklist to ensure that your patients have met all the conditions of prescription and have been informed about their treatment prior to initiation.**

### Initiating your patient on JINARC

About ADPKD	Completed
Review what ADPKD is, what causes it	<input type="checkbox"/>
Discuss symptoms of ADPKD	<input type="checkbox"/>
Answer patient questions about ADPKD	<input type="checkbox"/>
Key steps in the HSMD Programme	Completed
Review what JINARC is used for	<input type="checkbox"/>
Advise patient on potential risks and benefits of JINARC	<input type="checkbox"/>
Discuss the need for monthly liver function blood tests	<input type="checkbox"/>
Confirm baseline levels of ALT and AST are <3 times ULN, and ensure total bilirubin and alkaline phosphatase have been assessed	<input type="checkbox"/>
Inform women of childbearing potential that they should have effective contraceptive measures in place prior to and during JINARC use	<input type="checkbox"/>
Provide and review patient information brochure	<input type="checkbox"/>
Introduce the ORIJIN <sup>®</sup> Patient Support Program (PSP) and discuss its services	<input type="checkbox"/>
Review and co-sign the Patient-Prescriber Agreement Form (PPAF) with patient	<input type="checkbox"/>
Submit the PPAF to the HSMD Programme	<input type="checkbox"/>
Provide patient with monthly liver function test (LFT) (AST and ALT) orders up to the patient's follow-up visit	<input type="checkbox"/>
Taking JINARC	Completed
Review dosing, frequency and proper use	<input type="checkbox"/>
Discuss interactions with food/medications	<input type="checkbox"/>
Outline warnings: liver disorder	<input type="checkbox"/>
Outline warnings: pregnancy/breastfeeding/contraception	<input type="checkbox"/>
Discuss side effects and what to do about them	<input type="checkbox"/>
Review emergency situations (dehydration, allergic reactions, etc.)	<input type="checkbox"/>

**Consult the JINARC prescriber's guide for more information.**

To contact the HSMD Programme team:

Phone: 1-844-2JINARC  
(1-844-254-6272)

Fax: 1-844-3JINARC  
(1-844-354-6272)

## The ORIJIN<sup>®</sup> Patient Support Program

Key support services include:

For patients

- A personal coordinator for **reimbursement/financial assistance**
- Access to **nurses** who provide support to **initiate JINARC** and help answer questions about their treatment
- **Access to the Home Bloodwork Program or phone call reminders** for patients to go for blood tests and to support their treatment journey
- **Pharmacy services** and delivery of JINARC to the patient's home or work

For HCPs

- **Liver function tests** monitoring

For patients and HCPs

- Access to **JINARC.CA**, a website for both **patients** and **HCPs** with a newsletter program exclusive to patients

**For more information on ORIJIN, call: 1-844-2JINARC (1-844-254-6272)**

<sup>Pr</sup>JINARC<sup>®</sup> (tolvaptan) is indicated to slow the progression of kidney enlargement and kidney function decline in adult patients with autosomal dominant polycystic kidney disease (ADPKD). In ADPKD, kidney enlargement reflects renal cyst burden.<sup>1</sup>

ALT: alanine aminotransferase;  
AST: aspartate aminotransferase;  
ULN: upper limit of normal.

# A quick reference tool to facilitate initiation of <sup>Pr</sup>JINARC<sup>®</sup> for your patients

Use this checklist to monitor your patients during treatment.

## Monitoring your patient on JINARC

Key steps in the HSMD Programme	Completed
Review LFT results	<input type="checkbox"/>
Confirm levels of ALT and AST are <3 times ULN	<input type="checkbox"/>
Receive, complete, and submit LFT fax-back form to the HSMD Programme	<input type="checkbox"/>
Refer to JINARC Product Monograph for dose adjustment recommendations	<input type="checkbox"/>

**Please note that LFTs must be completed monthly for the first 18 months, every 3 months for the next 12 months, and every 3–6 months thereafter.**

Living with ADPKD and JINARC	Completed
Remind patient of the importance of adherence to treatment	<input type="checkbox"/>
Remind patient about ongoing monthly liver function tests during the first 18 months, every 3 months for the next 12 months, and then every 3-6 months thereafter	<input type="checkbox"/>
Advise patient to tell all his/her doctor(s), nurse(s) and pharmacist(s) that he/she is taking JINARC	<input type="checkbox"/>
Remind patient of the ongoing services provided by the ORIJIN <sup>®</sup> PSP	<input type="checkbox"/>
Direct patient to additional patient resources/support	<input type="checkbox"/>
Review patient goals and action plans (if applicable)	<input type="checkbox"/>
Set next appointment(s) with patient	<input type="checkbox"/>
Reminder: continue with your current practice of reporting safety information as required	<input type="checkbox"/>

Signature – Physician

Consult the Product Monograph at [jinarcmonograph.ca](http://jinarcmonograph.ca) for conditions of clinical use, contraindications, warnings, precautions, adverse reactions, interactions, dosing and monitoring. The Product Monograph is also available by calling 1-877-341-9245.

Reference: 1. <sup>Pr</sup>JINARC<sup>®</sup> Product Monograph. Otsuka Canada Pharmaceutical Inc.



All trademarks identified by a <sup>®</sup> or a <sup>™</sup> are protected trademarks (registered or unregistered) of their owners or licensors. For more information, please visit [www.otsukacanadatm-mc.ca](http://www.otsukacanadatm-mc.ca). © Otsuka Canada Pharmaceutical Inc. All rights reserved. OCPI-JIN-00251E

